Editas Medicine, Inc.
NASDAQ:EDITBiotechnology
+$0.07 today
- Market cap
- $273.18M
- Beta
- 2.10
- P/E (TTM)
- -2.4
- EPS (TTM)
- -$1.11
Volume 1.99M
Average 2.06M
EDIT EPS (Basic)
Net income attributable to common shareholders divided by the weighted average basic shares outstanding.
Editas Medicine, Inc.NASDAQ: EDIT
EPS (Basic) · Q1 FY2026 · quarter ended Mar 2026
EPS (Basic) remains negative
Q1 FY2026 EPS (Basic) was -$0.26, compared with -$0.92 a year earlier. Trailing-twelve-month EPS (Basic) was -$1.23.
Context
- EPS (Basic) grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Basic) reaches the consensus estimate from 8 analysts of -$0.75 (+58.5%) for the fiscal year ending Dec 2026, a step up from the +37.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$0.26-349.8% QoQ
- Last fiscal yearDec 2025
- -$1.8+37.5% YoY
- LTMMar 2026
- -$1.23+59.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +71.7% | +57.1% | -14.7 pp |
| 1 year | +37.5% | +58.5% | +21.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Basic) history
USD · from the income statement
- Latest · FY2025
- (1.80) USD
- Year-over-year change
- +37.5%
| Period | Period end | EPS (Basic) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.80) | +37.5% |
| FY2024 | 2024-12-31 | (2.88) | -42.6% |
| FY2023 | 2023-12-31 | (2.02) | +37.1% |
| FY2022 | 2022-12-31 | (3.21) | -12.6% |
| FY2021 | 2021-12-31 | (2.85) | — |
EPS (Basic) vs competitors
How EDIT compares with its peers on the latest reported figures
- EDIT's LTM Mar 2026 EPS (Basic) of -$1.23 is the 3rd highest of the 9 companies compared; the peer median is -$1.65.
- Its year-over-year change of +59.6% is the 2nd highest of 9, against a peer median of +26.2%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | -$0.82 | +81.8% | — | |
| LTM Mar 2026 | -$1.11 | +35.5% | — | |
| LTM Mar 2026 | -$1.23 | +59.6% | — | |
| LTM Mar 2026 | -$1.27 | +23.5% | — | |
| LTM Mar 2026 | -$1.42 | +12.3% | — | |
| LTM Mar 2026 | -$1.87 | +28.9% | — | |
| LTM Mar 2026 | -$3.54 | +32.3% | — | |
| LTM Mar 2026 | -$4.35 | -84.3% | — | |
| LTM Sep 2026 | -$4.74 | +15.2% | — | |
SCTXScribe Therapeutics Inc. | — | — | — | — |
| Peer median (excluding EDIT) | -$1.65 | +26.2% | — | |
Competitors are the stored peer set for EDIT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 25.54M | 19.71M | 78.12M | 32.31M | 40.52M |
| Cost of Revenue | 5.05M | 6.34M | 6.06M | 199.25M | 0 |
| Gross Profit | 20.49M | 13.38M | 72.06M | (166.93M) | 40.52M |
| Gross Margin | 80.2% | 67.9% | 92.2% | -516.6% | 100.0% |
| Research & Development | 142.51M | 174.96M | 177.65M | 199.25M | 89.95M |
| Selling, General & Admin | 76.18M | 70.7M | 69.65M | 71.99M | 49.9M |
| Operating Expenses | 213.64M | 239.33M | 241.24M | 84.22M | 139.86M |
| Depreciation & Amortization | 5.05M | 6.34M | 6.06M | 5.81M | 5.28M |
| EBITDA | (187.45M) | (214.1M) | (147.16M) | (233.11M) | (148.61M) |
| EBITDA Margin | -733.8% | -1086.1% | -188.4% | -721.4% | -366.8% |
| Operating Income | (193.15M) | (225.95M) | (169.18M) | (251.15M) | (99.34M) |
| Operating Margin | -756.1% | -1146.3% | -216.6% | -777.2% | -245.2% |
| Interest Income | 607K | 5.52M | 17.57M | 14.06M | 8.31M |
| Interest Expense | 0 | 0 | 0 | 0 | 6.17M |
| Other Income / Expenses | 644K | 5.52M | 15.96M | 14.06M | (60.72M) |
| Income Before Tax | (192.5M) | (220.43M) | (153.22M) | (237.09M) | (160.06M) |
| Pre-Tax Margin | -753.6% | -1118.3% | -196.1% | -733.7% | -395.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (192.5M) | (220.43M) | (153.22M) | (237.09M) | (160.06M) |
| Net Margin | -753.6% | -1118.3% | -196.1% | -733.7% | -395.0% |
| EPS (Basic) | (2.85) | (3.21) | (2.02) | (2.88) | (1.80) |
| EPS (Diluted) | (2.85) | (3.21) | (2.02) | (2.88) | (1.80) |
| Weighted Avg Shares | 67.62M | 68.66M | 75.97M | 82.34M | 88.75M |
| Weighted Avg Shares (Diluted) | 67.62M | 68.66M | 75.97M | 82.34M | 88.75M |
Editas Medicine, Inc.
NASDAQ:EDIT
Intrinsic Alpha fair value
Locked
Current Price
$1.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.